[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mouth-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mouth-cancer":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,66,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100602476","destiny-pantumour04-100602476",false,"NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","18 Years","130 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","RECRUITING","2026-06-26",{"date":56,"type":57},"2026-06-29","ACTUAL",{"date":59,"type":57},"2025-09-18",{"date":61,"type":22},"2028-03-30",{"name":63,"class":64},"AstraZeneca","INDUSTRY",17,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100612544","phase-2-capecitabine-prior-to-tumor-resection-in-ent-oncology-capture-100612544","NCT07254962","CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)","CAPTURE","Inclusion Criteria:\n\n* • Previously untreated, histologically confirmed non-HPV related HNSCC and radiologically or histologically confirmed stage I or IVA (AJCC 8th edition).\n\n  * No evidence of distant metastatic disease.\n  * Able to undergo protocol therapy, including necessary imaging and surgery.\n  * If female: may participate if not actively pregnancy nor breastfeeding.\n  * If male: must agree to refrain from donating sperm and must either be abstinent or agree to use contraception.\n  * Performance status (ECOG) of 0, 1 or 2.\n\nExclusion Criteria:\n\n* History of immunodeficiency, HBV, HCV, HIV. No HBV, HCV or HIV testing is required unless mandated by local health authority.\n* Active infection requiring systemic therapy.\n* Previous allogenic tissue\u002Fsolid organ transplant.\n* Known severe hypersensitivity (≥ Grade 3) to capecitabine, its active substance and\u002For any of its excipients.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Known DYPD mutation.\n* Known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Received prior systemic anticancer therapy including investigational agents for the current malignancy prior to allocation.\n* Currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.\n* Known additional malignancy that is progressing or requires active treatment within the past (5 years), excluding basal cell carcinoma or cutaneous squamous cell carcinoma.",{"count":74,"type":22},75,"INTERVENTIONAL",[77],"PHASE2","head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects areas such as the mouth, throat, and voice box. Despite medical progress, little has changed in the care for patients with HPV-negative cancer. The standard care involves surgery followed by radiation or chemotherapy if needed. However, delays in starting treatment - especially beyond six weeks - are linked to worse outcomes. Many patients also experience cancer returning within two years, often making it harder to treat. This study aims to improve outcomes by giving patients a short course of capecitabine, a chemotherapy pill, before surgery. Capecitabine is easier to tolerate than traditional intravenous chemotherapy and has shown promising results in shrinking tumors. Researchers believe that starting this oral treatment early could reduce delays, shrink tumors, make surgery less complex, and improve survival. The clinical trial will randomly assign patients with newly diagnosed stage III or IVa HPV-negative head and neck cancer to receive either standard care or capecitabine before surgery. Surgery will be performed within six weeks of diagnosis, followed by additional therapy as needed. The study will measure how well the tumor responds under the microscope after surgery, how much it shrinks on scans, the safety of the treatment, and cancer-free survival at two years. It will also explore biological markers linked to treatment response.\n\nIf successful, this approach could offer a simpler, faster, and more effective way to treat head and neck cancer, leading to earlier treatment, less invasive surgery, and improved patient outcomes. The study plans to include about 62 patients to evaluate the benefits of this new treatment strategy",[80,37,48,81,82],"Head Neck Cancer","Larynx Cancer","Skin Cancer Face",[84,85,86,87,88,89],"window of opportunity","surgery","neoadjuvant","capecitabine","Head and neck cancer","HPV-negative","NOT_YET_RECRUITING","2025-11-19",{"date":93,"type":57},"2025-11-28",{"date":95,"type":22},"2026-01-01",{"date":97,"type":22},"2031-01-01",{"name":99,"class":100},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100601448","real-time-molecular-diagnosis-of-oral-precancer-100601448","NCT07110623","Real-time Molecular Diagnosis of Oral Precancer","LIP","Inclusion criteria for patients\n\n1. Adult aged 18 and older\n2. One of the following criteria must be met:\n\n   1. Has a medical condition for which biopsy of oral tissue has been indicated.\n   2. Is undergoing inspection for early oral cancer\n3. Willing and able to comply with all study procedures.\n\nExclusion criteria for patients\n\n1. Has a bleeding disorder, such as haemophilia, or has contraindication for having a biopsy.\n2. Severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA) and rheumatoid arthritis (RA) requiring long term non-steroidal anti-inflammatory drug (NSAID) therapy and any other immunosuppression \u002F immuno-modulation therapy.\n3. Has other severe acute or chronic medical or psychiatric condition where use of the device may cause unnecessary stress\n4. Any condition that under judgment of the investigator would make the subject unsuitable as it may interfere with interpretation of study results\n5. Currently using any compound recognised as acting as a light sensitizer \u002F has a recognised condition associated with light sensitisation \u002F tissue sensitivity to light such as photodynamic therapy or lupus.\n6. Is pregnant or breastfeeding\n7. Has a laboratory abnormality in medical record that may interfere with the interpretation of study results\n\nInclusion criteria for healthy volunteers\n\n1. Adult aged 18 and older.\n2. Willing and able to comply with all study procedures.\n\nExclusion criteria for healthy volunteers\n\n1. Has a medical condition for which biopsy has been indicated or is undergoing inspection for early cancer.\n2. Severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA) and rheumatoid arthritis (RA) requiring long term non-steroidal anti-inflammatory drug (NSAID) therapy and any other immunosuppression \u002F immuno-modulation therapy.\n3. Has other severe acute or chronic medical or psychiatric condition where use of the device may cause unnecessary stress\n4. Any condition that under judgment of the investigator would make the subject unsuitable as it may interfere with interpretation of study results\n5. Currently using any compound recognised as acting as a light sensitizer \u002F has a recognised condition associated with light sensitisation \u002F tissue sensitivity to light such as photodynamic therapy or lupus.\n6. Is pregnant or breastfeeding",true,{"count":110,"type":22},40,"The \"Real-time molecular diagnosis of oral precancer\" or the LIP study is testing a new device for the detection of cancer in the mouth.\n\nOral cancers are serious and devastating illnesses, especially if detected at a late stage. Currently, the detection of oral cancer relies on testing a biopsy, which involves cutting a small section of tissue from the mouth and sending it to the pathology laboratory for further testing. A doctor or dentist taking the biopsy must rely on their own eyesight and experience to spot areas of concern. It can therefore be difficult to detect the earliest stages of cancer. At times, cancer tissue is only detected because it has already developed, and this affects the success of the treatment.\n\nThe device tested in this study uses a laser beam to scan areas inside the mouth and a computer collects information about the scan. The goal of this project is to train the computer software in the device to recognize pre-cancer and cancer from normal scans. Patients who need to have a biopsy due to suspected pre-cancer or cancer in the mouth will be scanned with the device. Biopsy reports will be used to tell the software which scans were from pre-cancer or cancer or non-cancer tissues. Volunteers with healthy oral tissue will be included to further test the computer software. Secondary aims include collecting pilot safety data and feedback regarding the use of this device. If successful, the results from this pilot study will lead to a bigger trial to further study how the device can be used for cancer diagnosis.",[113,114,115,116,37],"Oral Cancer","Dysplasia","Oral Lesions","Oral Pre-cancer",[118,119,120,121,122,123,124,125,126,127],"oral cancer","mouth lesions","dysplastic oral lesions","mouth cancer","pre-cancer","mouth pre-cancer","oral pre-cancer","oral lesions","oral biopsy","polarized Raman spectroscopy","2025-08-13",{"date":130,"type":57},"2025-08-19",{"date":132,"type":22},"2025-09-01",{"date":134,"type":22},"2025-10-31",{"name":136,"class":100},"King's College London",1]